 |
Dorset |
 |
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
Poole Hospital NHS Foundation Trust
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust |
|
| Formulary Chapter 3: Respiratory system - Full Section
|
Notes:
The Rightbreathe website is an online tool designed to assist with the selection, prescribing and on-going use of inhalers. It covers all inhaler and spacer devices licensed for asthma and COPD in the UK. Clinicians should note that the website refers to prescribing pathways in London and these may not be in line with those agreed in Dorset.
To view the British Lung Foundation COPD Patient Passport please click here |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
03.01 |
Bronchodilators
(0,1)
|
|
|
Asthma
(0,0)
|
|
|
Chronic obstructive pulmonary disease
(0,0)
|
|
|
Croup
(0,0)
|
|
03.01.01 |
Adrenoceptor agonists
(0,0)
|
|
03.01.01.01 |
Selective Beta2 agonists
(8,1)
|
|
03.01.01.02 |
Other adrenoceptor agonists
(0,2)
|
|
03.01.02 |
Antimuscarinic bronchodilators
(6,0)
|
|
|
Short Acting Anti-muscarinic Bronchodilators
(0,0)
|
|
|
Long Acting Anti-muscarinic Bronchodilators
(1,0)
|
|
03.01.03 |
Theophylline
(3,0)
|
|
03.01.04 |
Compound bronchodilator preparations
(5,1)
|
|
03.01.05 |
Peak flow meters, inhaler devices and nebulisers
(0,1)
|
|
|
Peak flow meters
(2,4)
|
|
|
Drug delivery devices
(5,8)
|
|
|
Nebulisers
(0,29)
|
|
|
Nebuliser Diluent
(0,1)
|
|
03.02 |
Corticosteroids
(12,2)
|
|
03.02.01 |
Inhaled Corticosteroids
(0,0)
|
|
03.02.02 |
Compound Corticosteroid/ Long acting beta-agonist inhalers
(0,0)
|
|
|
Low dose
(0,0)
|
|
|
Moderate dose
(0,0)
|
|
|
High dose
(0,0)
|
|
03.02.03 |
Combination products (ICS+LABA) for COPD
(0,0)
|
|
|
Triple Therapy products for COPD
(2,0)
|
|
03.03 |
Cromoglicate, related therapy and leukotriene receptor antagonists
(0,0)
|
|
03.03.01 |
Cromoglicate and related therapy
(1,0)
|
|
|
Related therapy
(0,0)
|
|
03.03.02 |
Leukotriene receptor antagonists
(2,0)
|
|
03.03.03 |
Phosphodiesterase type-4 inhibitors
(1,0)
|
|
03.04 |
Antihistamines, hyposensitisation, and allergic emergencies
(0,1)
|
|
03.04.01 |
Antihistamines
(0,0)
|
|
|
Non-sedating antihistamines
(3,6)
|
|
|
Sedating antihistamines
(3,5)
|
|
03.04.02 |
Allergen Immunotherapy
(3,3)
|
|
03.04.03 |
Allergic emergencies
(0,0)
|
|
|
Anaphylaxis
(2,0)
|
|
|
Angioedema
(3,0)
|
|
03.05 |
Respiratory stimulants and pulmonary surfactants
(0,0)
|
|
03.05.01 |
Respiratory stimulants
(2,0)
|
|
03.05.02 |
Pulmonary surfactants
(2,0)
|
|
03.06 |
Oxygen
(0,0)
|
|
|
Long-term oxygen therapy
(0,0)
|
|
|
Short burst oxygen therpary
(0,0)
|
|
|
Ambulatory oxygen therapy
(0,0)
|
|
|
Oxygen therapy equipment
(0,0)
|
|
|
Arrangements for supplying oxygen
(0,0)
|
|
03.07 |
Mucolytics
(2,3)
|
|
|
Dornase alfa
(1,0)
|
|
|
Hypertonic Sodium Chloride
(2,1)
|
|
|
Mannitol
(1,0)
|
|
03.08 |
Aromatic inhalations
(0,3)
|
|
03.09 |
Cough preparations
(0,1)
|
|
03.09.01 |
Cough suppressants
(0,5)
|
|
|
Palliative care
(1,0)
|
|
03.09.02 |
Expectorant and demulcent cough preparations
(0,3)
|
|
03.10 |
Systemic nasal decongestants
(0,1)
|
|
03.11 |
Antifibrotics
(2,1)
|
|
|
|
